Evommune, Inc. develops clinical-stage biotechnology therapies targeting key drivers of chronic inflammatory diseases. News about EVMN centers on its pipeline, including EVO756, an oral small-molecule MRGPRX2 antagonist, and EVO301, a long-acting IL-18 binding protein fusion protein.
Company updates commonly cover clinical data, development plans and regulatory disclosures for chronic spontaneous urticaria, atopic dermatitis, ulcerative colitis and migraine prophylaxis. Recurring corporate news also includes quarterly financial results, capital-structure actions, business updates and public-company milestones following Evommune’s completed initial public offering.
Evommune (NYSE: EVMN) reported positive top-line Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis. The 70-patient trial met its Bayesian primary endpoint with 99.8% posterior success and showed statistically significant, placebo-adjusted EASI reductions of 33% at week 12.
Additional highlights: 23% of patients achieved vIGA-AD 0/1 at week 12 versus 0% placebo, favorable PK supporting Q4-week dosing, no related serious adverse events, and plans for a Phase 2b subcutaneous dose-ranging trial.
Evommune (NYSE: EVMN) reported Q3 2025 results and a business update highlighting upcoming clinical milestones and its recent IPO. The company expects three Phase 2 readouts in 2026 across lead programs EVO756 (MRGPRX2 antagonist) and EVO301 (IL-18 inhibitor), including Phase 2b top-line data in CSU in 1H26 and Phase 2a/2b AD readouts in 1H–2H26. The company completed an IPO in November 2025, raising $172.5 million gross proceeds. Q3 financials: $10.0M revenue (collaboration with Maruho), $76.0M cash and investments as of Sept 30, 2025, R&D expense of $19.6M, and net loss of $12.5M.
Evommune (NYSE:EVMN) priced its initial public offering of 9,375,000 common shares at $16.00 per share, with gross proceeds expected to be $150 million before underwriting discounts, commissions, and expenses. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares.
The shares are expected to begin trading on the New York Stock Exchange on November 6, 2025 under ticker EVMN, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.
Evommune (NYSE:EVMN) announced the commencement of a proposed initial public offering on October 17, 2025 with a registration statement filed on Form S-1.
The company is offering 9,375,000 shares of common stock with an expected price range of $15.00 to $17.00 per share, and intends to grant underwriters a 30-day option for up to 1,406,250 additional shares. Evommune has applied to list its shares on the New York Stock Exchange under the symbol EVMN, and expects the registration statement to become automatically effective on November 5, 2025 pursuant to Section 8(a) of the Securities Act, subject to SEC and federal government operations.